Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $8.9 million.

  • Gossamer Bio's Cash & Equivalents fell 6861.65% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year decrease of 6861.65%. This contributed to the annual value of $46.1 million for FY2024, which is 4349.25% up from last year.
  • Latest data reveals that Gossamer Bio reported Cash & Equivalents of $8.9 million as of Q3 2025, which was down 6861.65% from $26.3 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Cash & Equivalents high stood at $153.5 million for Q3 2022, and its period low was $8.9 million during Q3 2025.
  • For the 4-year period, Gossamer Bio's Cash & Equivalents averaged around $65.3 million, with its median value being $46.1 million (2024).
  • In the last 5 years, Gossamer Bio's Cash & Equivalents tumbled by 7132.43% in 2023 and then surged by 13477.73% in 2024.
  • Quarter analysis of 4 years shows Gossamer Bio's Cash & Equivalents stood at $112.0 million in 2022, then plummeted by 71.32% to $32.1 million in 2023, then surged by 43.49% to $46.1 million in 2024, then crashed by 80.61% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $26.3 million for Q2 2025, and $29.0 million during Q1 2025.